Abstract
Nonspecific vaginitis (NSV) is an extremely common problem that is of great medical and social importance, especially in the population of women of childbearing age. It seems necessary to study the possibilities of using new topical combination drugs made in Russia for the treatment of NSV, which would not be inferior or superior to foreign analogues in efficiency, safety, and ease of use. Objective. To investigate the efficacy and safety of Targyfort in two parallel groups of 360 women aged 18 to 45 years with a clinical diagnosis of acute vaginitis specified by laboratory assays. The aim was to assess the frequency of complete recovery in the study group at 14 days after treatment completion. The duration of therapy was 10 days in both groups. Subjects and methods. The open-label comparative randomized multicenter clinical trial was conducted in the Russian Federation in 2017-2018. This evaluated the efficacy and safety of Targyfort vaginal suppositories (OAO “Avexima”, Russia) and Tergynan vaginal tablets (Laboratoires Bouchara-Recordati, France) in the treatment of vaginitides of various etiologies. Results. The investigation shows that the efficacy of the Russian drug Targyfort in a number of very important indicators that directly affect quality of life in patients is not lower (no pain (98.3%), burning (97.8%), and itching (98.9%) in the Targyfort group and 98.3, 97.8, and 95.4% in the Tergynan group), whereas the rate of disappearance of the symptoms of pain and burning (4.3 and 4.8 days) is statistically significantly higher than that of Tergynan (5.6 and 5.8 days). Conclusion. The results of the investigation make it possible to recommend Targyfort for the treatment of vaginitides of various etiologies in women of childbearing age as an effective and safe therapeutic drug that is convenient for self-use.
Open Access
Access granted
